As promised, Novartis eyes new method for funding ultrapricey next-gen drugs: FT
admin 17th December 2018 Uncategorised 0Novartis is weighing an insurance method often associated with natural disasters to help win coverage for its pricey next-generation cell and gene therapies. Reinsurance would underwrite a different sort of catastrophe, Novartis CEO Vas Narasimhan told the Financial Times.
More: As promised, Novartis eyes new method for funding ultrapricey next-gen drugs: FT
Source: fierce
